Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safrazine SCHEMBL29359452 | 1.00 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Safrazine SCHEMBL1868031 | 0.98 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10395528 | 0.84 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL987525 | 0.83 | TAAR1 (0.71) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL8294114 | 0.82 | TAAR1 (0.61) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL31303188 | 0.80 | TAS1R3 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2485767 | 0.80 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29664514 | 0.80 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL28123545 | 0.80 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10715342 | 0.79 | ALDH1A1 (0.64) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | Intrabio Ltd. (GB) | 2024-10-22 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | claimed |
| EP-1991248-A2 | ANTIDEPRESSANT PRODRUGS | Shire LLC (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007100668-A2 | ANTIDEPRESSANT PRODRUGS | SHIRE LLC (US) | 2007-09-07 | — | — | WO | claimed |
| US-20060287299-A1 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE J | 2006-12-21 | — | — | US | claimed |
| EP-1713486-A1 | COMBINATION THERAPY FOR DEMENTIA,DEPRESSION AND APATHY | Sheldon, Leslie James (CA) | 2006-10-25 | — | — | EP | claimed |
| US-6946141-B2 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS, INC. (US) | 2005-09-20 | — | — | US | claimed |
| WO-2005053703-A1 | COMBINATION THERAPY FOR DEMENTIA, DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2005-06-16 | — | — | WO | claimed |
| WO-2004041207-A2 | GHB TREATMENT METHODS | BAYLOR RESEARCH INSTITUTE (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1389115-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | TAAR1 150/4885SLC6A4 214/4885SLC6A2 160/4885 |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | CDR2, OPRL1, TPH1 | TAAR1 350/4885SLC6A4 221/4885SLC6A2 314/4885 |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | HNMT, MAOA, MAOB | TAAR1 655/4885SLC6A4 73/4885SLC6A2 6/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | TAAR1 55/4885SLC6A4 36/4885SLC6A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.